Roche Pharma India has launched two innovative medicines Perjeta and Kadcyla for the treatment of HER2-positive metastatic breast. The new drugs have been shown to both extend survival and improve quality of life in their approved applications for metastatic HER2-positive breast cancer. Perjeta is approved in combination with trastuzumab (Herclon) and docetaxel chemotherapy for people with previously untreated HER2-positive metastatic breast disease (first-line treatment). Kadcyla is approved for people with HER2-positive metastatic breast disease previously treated with trastuzumab (Herclon) and taxane chemotherapy (second-line treatment).
Company Profile : Roche Products India Pvt Ltd
Leave a Reply